Invasive oesophageal candidiasis: Current and developing treatment options

Research output: Contribution to journalReview article

36 Citations (Scopus)

Abstract

Oesophageal candidiasis is frequently one of the first signs of HIV infection, and a marker of HIV disease. Approximately 10% of patients with AIDS or other immunodeficiency, whether due to an underlying disease, chemotherapy or radiation therapy, will experience oesophageal candidiasis during their lifetime. In addition, unless the underlying immunodeficiency is corrected, approximately 60% of patients will experience a relapse within 6 months of the initial infection. The systemic azoles have gradually replaced the use of amphotericin B for oesophageal candidiasis, and are generally safely used and effective agents for this infection. A concern in some of these patients is the appearance of antifungal-refractory oesophageal candidiasis, which frequently leads to a vicious cycle of poor oral intake, weight loss, malnutrition and wasting syndrome, with occasional mortality due to malnutrition. Newer antifungals such as voriconazole and caspofungin, which are more potent in vitro and have a broader spectrum of activity, including activity against fluconazole-resistant Candida species are a welcome addition to the antifungal armamentarium that may be used in the management of refractory mucosal candidiasis.

Original languageEnglish (US)
Pages (from-to)971-989
Number of pages19
JournalDrugs
Volume63
Issue number10
DOIs
StatePublished - May 24 2003

Fingerprint

Invasive Candidiasis
Candidiasis
caspofungin
Malnutrition
Wasting Syndrome
Therapeutics
Azoles
Fluconazole
Amphotericin B
Infection
Candida
HIV Infections
Weight Loss
Acquired Immunodeficiency Syndrome
Radiotherapy
HIV
Recurrence
Drug Therapy
Mortality

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Invasive oesophageal candidiasis : Current and developing treatment options. / Vazquez, Jose Antonio.

In: Drugs, Vol. 63, No. 10, 24.05.2003, p. 971-989.

Research output: Contribution to journalReview article

@article{ddea1a1703b04fa58abc8d2d2c07d95f,
title = "Invasive oesophageal candidiasis: Current and developing treatment options",
abstract = "Oesophageal candidiasis is frequently one of the first signs of HIV infection, and a marker of HIV disease. Approximately 10{\%} of patients with AIDS or other immunodeficiency, whether due to an underlying disease, chemotherapy or radiation therapy, will experience oesophageal candidiasis during their lifetime. In addition, unless the underlying immunodeficiency is corrected, approximately 60{\%} of patients will experience a relapse within 6 months of the initial infection. The systemic azoles have gradually replaced the use of amphotericin B for oesophageal candidiasis, and are generally safely used and effective agents for this infection. A concern in some of these patients is the appearance of antifungal-refractory oesophageal candidiasis, which frequently leads to a vicious cycle of poor oral intake, weight loss, malnutrition and wasting syndrome, with occasional mortality due to malnutrition. Newer antifungals such as voriconazole and caspofungin, which are more potent in vitro and have a broader spectrum of activity, including activity against fluconazole-resistant Candida species are a welcome addition to the antifungal armamentarium that may be used in the management of refractory mucosal candidiasis.",
author = "Vazquez, {Jose Antonio}",
year = "2003",
month = "5",
day = "24",
doi = "10.2165/00003495-200363100-00004",
language = "English (US)",
volume = "63",
pages = "971--989",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "10",

}

TY - JOUR

T1 - Invasive oesophageal candidiasis

T2 - Current and developing treatment options

AU - Vazquez, Jose Antonio

PY - 2003/5/24

Y1 - 2003/5/24

N2 - Oesophageal candidiasis is frequently one of the first signs of HIV infection, and a marker of HIV disease. Approximately 10% of patients with AIDS or other immunodeficiency, whether due to an underlying disease, chemotherapy or radiation therapy, will experience oesophageal candidiasis during their lifetime. In addition, unless the underlying immunodeficiency is corrected, approximately 60% of patients will experience a relapse within 6 months of the initial infection. The systemic azoles have gradually replaced the use of amphotericin B for oesophageal candidiasis, and are generally safely used and effective agents for this infection. A concern in some of these patients is the appearance of antifungal-refractory oesophageal candidiasis, which frequently leads to a vicious cycle of poor oral intake, weight loss, malnutrition and wasting syndrome, with occasional mortality due to malnutrition. Newer antifungals such as voriconazole and caspofungin, which are more potent in vitro and have a broader spectrum of activity, including activity against fluconazole-resistant Candida species are a welcome addition to the antifungal armamentarium that may be used in the management of refractory mucosal candidiasis.

AB - Oesophageal candidiasis is frequently one of the first signs of HIV infection, and a marker of HIV disease. Approximately 10% of patients with AIDS or other immunodeficiency, whether due to an underlying disease, chemotherapy or radiation therapy, will experience oesophageal candidiasis during their lifetime. In addition, unless the underlying immunodeficiency is corrected, approximately 60% of patients will experience a relapse within 6 months of the initial infection. The systemic azoles have gradually replaced the use of amphotericin B for oesophageal candidiasis, and are generally safely used and effective agents for this infection. A concern in some of these patients is the appearance of antifungal-refractory oesophageal candidiasis, which frequently leads to a vicious cycle of poor oral intake, weight loss, malnutrition and wasting syndrome, with occasional mortality due to malnutrition. Newer antifungals such as voriconazole and caspofungin, which are more potent in vitro and have a broader spectrum of activity, including activity against fluconazole-resistant Candida species are a welcome addition to the antifungal armamentarium that may be used in the management of refractory mucosal candidiasis.

UR - http://www.scopus.com/inward/record.url?scp=0038706040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038706040&partnerID=8YFLogxK

U2 - 10.2165/00003495-200363100-00004

DO - 10.2165/00003495-200363100-00004

M3 - Review article

C2 - 12699400

AN - SCOPUS:0038706040

VL - 63

SP - 971

EP - 989

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 10

ER -